Patient cohort
| Characteristic . | Value . |
|---|---|
| No. of patients, n (%) | 70 (100) |
| Adult cases | 47 (67.1) |
| Elderly (aged ≥60 y) | 25 (35.7) |
| Adult (aged 40-59 y) | 16 (22.9) |
| Young adult (aged 19-39 y) | 6 (8.6) |
| Pediatric cases | |
| Adolescent (aged 15-18 y) | 2 (2.9) |
| Child (aged 3-14 y) | 14 (20.0) |
| Infant (aged <3 y) | 7 (10.0) |
| Sex, female | 37 (52.9) |
| Background | |
| De novo AML | 63 (90.0) |
| Potential t-AML | 3 (4.3) |
| MDS-AML | 2 (2.9) |
| t-MDS-AML | 2 (2.9) |
| No. of tumor samples, n (%) | 122 (100) |
| Diagnosis | 43 (35.2) |
| Relapse | 73 (59.9) |
| R1 and R1-P | 57 (46.7) |
| R2 and R2-P | 13 (10.7) |
| R3 | 3 (2.5) |
| Primary resistant | 6 (4.9) |
| Average age at onset, y | |
| Adult cases | 59.5 (range, 20.5-83.1; median, 62.2) |
| Pediatric cases | 7.7 (range, 0.4-17.5; median, 7.3) |
| Average length of EFS (D>R1), d | |
| Adult relapse cases | 497 (range, 34-3844; median, 305.0) |
| Pediatric relapse cases | 334 (range, 69-1026; median, 304.5) |
| Average length of OS, d | |
| Adult relapse cases | 1109 (range, 45-8270; median, 509) |
| Pediatric relapse cases | 1682 (range, 126-6557; median, 572) |
| Sample purity* | 89% (>80% tumor cells; range, 41-100) |
| Cell viability | 63% (≥75% viable cells; range, 10-94) |
| Average RIN | 9.2 (range, 5.8-10.0; median, 9.3) |
| Sampling duration | 1995-2016 |
| Characteristic . | Value . |
|---|---|
| No. of patients, n (%) | 70 (100) |
| Adult cases | 47 (67.1) |
| Elderly (aged ≥60 y) | 25 (35.7) |
| Adult (aged 40-59 y) | 16 (22.9) |
| Young adult (aged 19-39 y) | 6 (8.6) |
| Pediatric cases | |
| Adolescent (aged 15-18 y) | 2 (2.9) |
| Child (aged 3-14 y) | 14 (20.0) |
| Infant (aged <3 y) | 7 (10.0) |
| Sex, female | 37 (52.9) |
| Background | |
| De novo AML | 63 (90.0) |
| Potential t-AML | 3 (4.3) |
| MDS-AML | 2 (2.9) |
| t-MDS-AML | 2 (2.9) |
| No. of tumor samples, n (%) | 122 (100) |
| Diagnosis | 43 (35.2) |
| Relapse | 73 (59.9) |
| R1 and R1-P | 57 (46.7) |
| R2 and R2-P | 13 (10.7) |
| R3 | 3 (2.5) |
| Primary resistant | 6 (4.9) |
| Average age at onset, y | |
| Adult cases | 59.5 (range, 20.5-83.1; median, 62.2) |
| Pediatric cases | 7.7 (range, 0.4-17.5; median, 7.3) |
| Average length of EFS (D>R1), d | |
| Adult relapse cases | 497 (range, 34-3844; median, 305.0) |
| Pediatric relapse cases | 334 (range, 69-1026; median, 304.5) |
| Average length of OS, d | |
| Adult relapse cases | 1109 (range, 45-8270; median, 509) |
| Pediatric relapse cases | 1682 (range, 126-6557; median, 572) |
| Sample purity* | 89% (>80% tumor cells; range, 41-100) |
| Cell viability | 63% (≥75% viable cells; range, 10-94) |
| Average RIN | 9.2 (range, 5.8-10.0; median, 9.3) |
| Sampling duration | 1995-2016 |
Detailed biological and clinical data for each patient/sample are presented in supplemental Tables 2 and 3. D, diagnosis; EFS, EFS as time to first relapse; MDS, myelodysplastic syndromes; OS, OS as time to death or last follow-up; R1/2/3, sequential relapses; R1/2-P, persistent relapse specimen; RIN, RNA integrity number; t-AML, treatment-related AML.
Single-nucleotide polymorphism–based calculation.